DORYX MPC
Peakdoxycycline hyclate
NDAORALTABLET, DELAYED RELEASE
Approved
May 2005
Lifecycle
Peak
Competitive Pressure
0/100
Mechanism of Action
tetracycline-class antimicrobial drug [ see ].
Indications (21)
Rocky Mountain spotted fevertyphus feverthe typhus groupQ feverrickettsialpoxtick fevers caused by Rickettsiaethe following sexually transmitted infections: Uncomplicated urethralendocervicalrectal infections caused by Chlamydia trachomatisthe following respiratory infections: Respiratory tract infections caused by Mycoplasma pneumoniaeinfections caused by the following micro- organismsbacteriological testing indicates appropriate susceptibility to the drug: – Respiratory tract infections caused by Haemophilus influenzaethe following specific bacterial infections: Relapsing fever due to Borrelia recurrentisinfections caused by the following gram- negative microorganismsthe following ophthalmic infections: Trachoma caused by Chlamydia trachomatisalthough the infectious agent is not always eliminatedanthrax due to Bacillus anthracisincluding inhalational anthrax (post-exposure): to reduce the incidenceprogression of disease following exposure to aerosolized Bacillus anthracismalaria due to Plasmodium falciparum in short-term travelers (less than 4 months) to areas with chloroquine and/or pyrimethamine-sulfadoxine resistant strains [ seeincidence
Loss of Exclusivity
LOE Date
Dec 23, 2034
107 months away
Patent Expiry
Dec 23, 2034